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Exercise: Treatment for NAFLD
The most efﬁcient strategy to treat chronic liver disease including
NAFLD is to remove the cause (i.e., hypocaloric diet and aerobic exer-
cise in patients with NAFLD). Although aerobic exercise reduces liver
fat and visceral adipose tissue, there are limited prospective studies
assessing the effect of different exercise programs. The study from
Keating et al. investigated the effects of different programs of aerobic
exercise (low to moderate intensity, high volume vs. high intensity, low
volume aerobic). The authors found that both aerobic exercise regi-
mens reduced liver and visceral fat and VAT without signiﬁcant
weight loss. This important study supports that exercise should be
advised, when possible, to patients with NAFLD. For patients unable
to modify their lifestyle, targeted therapies are needed.Dying non-tumoral cells release
danger-associated molecular
patterns (DAMPs) of different
subcellular origin, e.g., the
nuclear, non-histone protein,
high mobility group box-1
(HMGB1) or mitochondrial DNA
(mtDNA), among others. In the
context of auto-immune dis-
eases HMGB1 is an essential
component of DNA-containing
immune complexes that stimu-
late cytokine production through
a TLR9 pathway. Interestingly,
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PDGFR-b as a target for
anti-ﬁbrotic therapy
Platelet-derived growth factor
receptor beta (PDGFR-b)
belongs to the large family of
receptor tyrosine kinases
(RTKs) that are expressed at the
cell-surface. Rapid induction of
PDGFR-b is a hallmark of hep-
atic stellate cell activation; how-
ever, little is known on its cellular
impact in vivo. To address this
question Kocabayoglu et al.
used in vitro approaches, in vivo
mice models of liver injury and
HCC, and a cohort of patients
with hepatitis C virus-related cir-
rhosis (with or without HCC).
They found that PDGFR-b is a
key mediator of liver injury
and ﬁbrogenesis in vivo and
contributes to the poor prog-
nosis of human cirrhosis, but
not by increasing HCC devel-
opment. Together these ﬁndings
deserve two comments: ﬁrst,
PDGFR-b is an attractive anti-
ﬁbrotic target; and second, unlike
other RTK pathways such as
epidermal growth factor recep-
tor, PDGFR-b may not be a
suitable direct target to inhibit the
development of HCC.
LIVER
CARCINOGENESIS
Nuclear and
mitochondrial DAMPs
collaborate to promote
liver cancer
Toll-like receptor (TLR) 9,
expressed in endosomes of
innate immune cells, recognize
bacterial and viral DNA contain-
ing the unmethylated cyto
sine–phosphate–guanine
(CpG) dideoxynucleotide
motif. TLR9 recognition of CpG-
containing DNA (CpG-DNA)
triggers MyD88-mediated
inﬂammation. There is evidence
that TLR9 can also be activated
by ‘non-microbial’ CpG-DNA.Journal of Hepatology 2015 vol. 63 j 1–4
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mtDNA has similarities to bacte-
rial DNA, which contains
unmethylated CpG motifs. After
severe trauma, released mtDNA
can activate innate immune cells
via TLR9 engagement. Liu et al.
reasoned that cell death result-
ing from hypoxia at the center of
the HCC tumor may release
HMGB1 and mtDNA and this
would contribute to inﬂammation
and tumor promotion. They
address their hypothesis using
in vivo and in vitro approaches
and provide convincing results
(this issue of the Journal) show-
ing that interactions of HMGB1
and mtDNA activate TLR9 sig-
naling during hypoxia to
induce HCC growth.
THERAPIES FOR LIVER
CANCER
Targeting cyclin-
dependent-like kinase 5,
predicting outcome of
treated HCC
It has long been known that
cyclin-dependent-like kinase 5
(CDK5) is essential for neuronal
cell cycle arrest and differentia-
tion. Moreover, it has recently
been suggested that CDK5 is
involved in cancer progression.
Using different approaches
including expression microarray
in human HCC tissue Ehrlich
et al. investigated CDK5 as a
potential target for treating
patients with HCC. They found
that CDK5 inhibition combined
to DNA damaging agents is a
novel therapeutic approach
for HCC.
Several staging systems are
used to predict survival in
patients with HCC. However, the
ability of most of these staging
systems in predicting survival in
patients with unresectable HCC
after transarterial chemoem-
bolization (TACE) is limited. Xu
et al. addressed this question by
constructing a nomogram based
on data obtained from a retro-
spective study on 2938 patients
who received TACE as an initial
therapy from 2000 to 2008. Por-
tal vein invasion, tumor number,
tumor capsule, a-fetoprotein,
aspartate aminotransferase, and
indocyanine green retention at
15 min were the basis of the
nomogram. The nomogram gave
better discrimination than the
seven other well-established
staging systems. Therefore, the
proposed nomogram provides
accurate prognostic predic-
tion in patients with unre-
sectable HCC after treatment
with TACE.
In the context of HCC, the
beneﬁt of TACE prior to liver
resection or transplantation is
unclear. Allard et al. hypothe-
sized that the amount of TACE-
induced tumor necrosis
assessed by two expert pathol-
ogists on surgical specimens
could provide prognostic infor-
mation. They investigated 373
cirrhotic patients with HCC trea-
ted ﬁrst by TACE and then by
liver resection (n = 184) or
transplantation (n = 184). The
response assessed by pathol-
ogists (RAP) was the mean
percentage of non-viable tumor
area within each tumor. Com-
plete RAP was deﬁned as the
absence of any viable tumor
area in all the present nodules.
They found that a complete or
nearly complete RAP is asso-
ciated with higher long-term
survival after liver resection or
transplantation, independent of
other pathological factors. These
ﬁndings support, prior to surgery
for HCC, the use of therapies
that induce signiﬁcant decreases
in the active tumor load.
The incidence of metabolic
syndrome (MS)-associated
with HCC (MS-HCC) is increas-
ing. Little is known on the out-
comes after liver resection in
patients with MS-HCC. This is
why Vigano et al. investigated
retrospectively 1563 consecutive
patients who underwent liver
resection for HCC in six high-
volume liver units in 12 years.
Patients with MS-HCC were
matched with HCV-related HCC
patients who did not have MS.
They found that liver resection
was safe in patients with HCC
and MS as well as in patients
with HCV-related HCC and no
MS. Cirrhosis, but not steato-
hepatitis, was the main predictor
of poor short-term outcomes.
MS-HCC was associated with
excellent long-term outcomes,
better than outcomes in
patients with HCV-related HCC
and no MS.
NON-ALCOHOLIC
FATTY LIVER DISEASE
(NAFLD)
Nuclear receptors,
hypoxia-inducible
factor
Three studies in this issue pro-
pose novel targets for therapy for
NAFLD. Francque et al. provide
consistent human data implicat-
ing peroxisome proliferator-
activated receptors (PPARs) in
the pathogenesis of NASH. They
found that hepatic PPARa gene
expression negatively correlated
with NASH severity, visceral
adiposity and insulin resistance,
suggesting that it could be a
therapeutic target in NASH.
Wang et al. now investigate the
role of hepatic estrogen recep-
tor a (ERa) in triglyceride
homeostasis and fatty liver
development. Female mice
receiving ovariectomy or genetic
ablation of the ERa receptor
genetic ablation induced hepatic
triglyceride accumulation, while
overexpression of ERa amelio-
rated hepatosteatosis in obese
mice. These ﬁndings reveal a
novel role of estrogen in improv-
ing hepatosteatosis.
ALCOHOLIC LIVER
DISEASE (ALD)
Wnt-induced liver
protection
The molecular mechanisms of
ALD are partially known. In this
issue, Huang et al. demonstrate
a critical role for the Wnt/b-
catenin signaling pathway, which
restored attenuation of ALD in
rats. The authors also demon-
strated that this effect was
associated with a blockade of
Foxo3A-induced apoptosis.
Drugs targeting this pathway
could be beneﬁcial for patients
with ALD.
GENETIC METABOLIC
DISORDERS
Variants associated
with steatosis in
Wilson’s disease
Patients with Wilson’s disease
often have hepatic steatosis, yet
the underlying mechanisms are
largely unknown. In this issue,
Sta¨ttermayer et al. provide evi-
dence that steatosis is common
in these patients and the
PNPLA3 G allele contributes to
its pathogenesis. They also pro-
pose a potential role for hepatic
copper content and ATP7B (for
ATPase, Cu++ transporting,
beta polypeptide) mutations in
steatosis development, yet the
precise mechanisms deserve
future investigations. This study
suggests that, regardless of the
etiology, PNPLA3 is an important
genetic determinant of hepatic
steatosis.
HEPATITIS C
Quadruple therapy for
HCV type 1 and 4 non
responders, attention to
drug-drug interactions
(DDI), CMV infection of
sinusoidal endothelial
cells
The all oral combination of the
protease inhibitor asunaprevir
plus the NS5A inhibitor dacla-
tasvir has demonstrated high
efﬁcacy in HCV subtype 1b but
not 1a infection. A large open-
label, phase 3 study
(HALLMARK-QUAD) in a difﬁcult
to treat population of mainly null
responder patients with HCV
type 1 and 4 infection was
prospectively evaluated by Jen-
sen et al. to determine if adding
peginterferon plus ribavirin in
order to get a full quadruple
regimen applied for 24 weeks is
able to overcome these limita-
tions. SVR rates of 100% in HCV
JOURNAL OF HEPATOLOGY
2 Journal of Hepatology 2015 vol. 63 j 1–4
type 4, 99% in HCV subtype 1b,
and 87% in subtype 1a highlight
to the overall effectiveness of the
regimen. Interestingly, however,
adding peginterferon and rib-
avirin did not completely
abrogate HCV subtype 1a
effects especially for those har-
bouring protease- and or NS5A-
inhibitor associated baseline
resistant variants.
Attention to DDI is highly rel-
evant for the judicious use of
HCV direct-acting antiviral (DAA)
regimen as all DAA have the
potential to interact with drug
metabolizing enzymes and/or
drug transporters. The study by
Menon et al. represents the ﬁrst
comprehensive evaluation of
DDIs for the 3D regimen of
ombitasvir, paritaprevir/ritonavir
and dasabuvir and medications
likely to be co-prescribed in
HCV-infected patients also
including opioid substitution
substances. Although the major-
ity of the commonly used medi-
cations can be co-administered
with the regimen without dose
adjustment, gemﬁbrozil, carba-
mazepine and ethinyl estradiol-
containing contraceptives are
contraindicated. Findings are of
signiﬁcant importance for the
appropriate clinical manage-
ment, which sometimes requires
dose adjustments or discontinu-
ation of contraindicated
medications.
Human cytomegalovirus 1
(HCMV) infection can promote
hepatic inﬂammation and facili-
tate chronic organ rejection in
liver transplant recipients. By an
extensive set of experiments,
Bruns et al. now elegantly
describes that HCMV infection
of human sinusoidal endothe-
lial cells plays a crucial role in
modulating the recruitment
and differentiation of T cell
subsets thereby providing
important novel insights into the
mechanism of how HCMV infec-
tion is able to enhance hepatic
immune activation.
HEPATITIS B
CD8+ T cell response
and HBV immune
control
Although a strong CD8+ T cell
response is associated with
spontaneous HBsAg clearance
after acute hepatitis B virus
(HBV) infection its role in main-
taining immune control in the
long-term is rather unclear.
Reactivation of HBV infection in
immune controlled patients has
been linked, however, to mono-
clonal antibody-induced B cell
depletion (i.e., rituximab). In line
with these clinical observations,
Kefalakes et al. now demon-
strate that HBeAg-speciﬁc
CD8+ T cells continuously
decline after HBsAg clearance
suggesting that humoral and not
CD8+ T cell immune responses
mainly contribute to the preven-
tion of HBV reactivation decades
after HBsAg clearance.
CIRRHOSIS
Mechanism of cell death
in ACLF, role of HAV-
cr2/TIM-3 in mediating
risk of infection in
patients with
decompensated
cirrhosis
The mechanism of cell death is
unknown in patients with acute
on chronic liver failure (ACLF). In
patients with alcoholic cirrhosis,
who develop ACLF, the pre-
dominant mechanism of liver
injury is apoptosis and bilirubi-
nostasis is the main histological
ﬁnding. Li et al. describe impor-
tant data from patients with
ACLF due to hepatitis B from
China, where histological char-
acteristics of the livers were
studied in organs obtained at
transplantation. Their data sug-
gest that the predominant
mode of cell death in ACLF is
sub-massive hepatic necrosis,
which they suggest to be a
diagnostic hallmark. Infection
and inﬂammation are the conse-
quence of altered host response
to injury in cirrhosis. Shi et al.
provide novel data that, hepati-
tis A virus cellular receptor 2
(HAVcr-2, also known as T cell
immunoglobulin domain and
mucin domain-containing
molecule-3 (TIM-3)) is down
regulated in the circulating
monocytes in decompensated
cirrhosis due to Hepatitis B
virus infection. This ﬁnding may
be important in explaining the
basis of increased sensitivity to
endotoxin in this situation and
may well be a future target of
therapy.
LIVER
TRANSPLANTATION
Novel approach to
reduce graft failure of
donor cardiac death
(DCD) organs and
modulation of
acetaminophen (APAP)-
induced ALF with
metformin
The risk of post-transplantation
complications and graft failure is
higher in patients transplanted
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with DCD organs. Liu et al.
describe a novel approach to try
and reduce injury to the donor
organ. They use liver transplan-
tation techniques in the mouse to
show that inhibition of or the
absence of iNOS, JNK inhibi-
tion and JNK 2 deﬁciency are
targets of therapy. The down-
stream mechanism of this pro-
tective effect is via inhibiting
mitochondrial depolarization.
Kim et al. describe a potential
novel approach to the preven-
tion and treatment of APAP-
induced acute liver failure
(ALF) in ALF mice using, a
safe and widely used drug,
metformin. The mechanism of
this protective effect of met-
formin is through growth arrest
and DNA damage-inducible 45
beta (Gadd45b)-dependent reg-
ulation of the JNK pathway.
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Hypoxia induces release of
mtDNA from mitochondria
Hypoxia induces release of
HMGB1 from nucleus Tumor growth
Activation of growth
signaling pathways
HMGB1 and mtDNA bind
together in the cytosol HMGB1-mtDNA interacts
with TLR9 on endosomes
TLR9
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HMGB1
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ACLF pathological feature
Cholestasis
Ductular bilirubinostasis
(sepsis)
Residual cirrhotic
nodule
P : portal areas
V : terminal hepatic vein (central vein)
R : regenerative ductular (periportal region)
C : central part of necrosis
SMHN : completed disappearance of hepatocytes
              in wild area
Acute deterioration 
of hepatic functions
Multiple organ 
failure
Deranged systemic
inflammatory responses
Severity
TB, INR, Cr, MELD score
Acute deteriorating manner for progress
Dynamic changes of those parameters from
enrollment to LT
Deranged pro/anti-inflammatory cytokines 
in both serum and liver tissue
Organ failure index
CLIF-SOFA, SOFA score
ACLF clinical characteristic
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